Finnish protein manufacturer Vectron Biosolutions AS has completed a study comparing different expression technologies. According to Vectron, their proprietary E. coli expression technology gave higher yields for seven out of ten tested biosimilar proteins, including interferons, several interleukins and insulin. The yield from fermentation increased from two- to sevenfold, whereas in insoluble fraction increases of up to 25-fold were reported. “Demonstrating that our technology is superior for the manufacture of many valuable therapeutic proteins is a major milestone for us,” commented CEO Trond Erik Vee Aune. The biosimilars market is highly competitive, which makes cost-efficient manufacturing processes essential.